scholarly journals Retrograde Amnesia in Parkinson’s Disease

1984 ◽  
Vol 11 (2) ◽  
pp. 297-301 ◽  
Author(s):  
Morris Freedman ◽  
Peter Rivoira ◽  
Nelson Butters ◽  
Daniel S. Sax ◽  
Robert G. Feldman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Retrograde Amnesia ◽  
Memory Loss ◽  
Remote Memory ◽  
Time Periods ◽  
Alzheimer’S Diseases ◽  
Normal Controls ◽  
Alzheimer's Diseases

ABSTRACT:Retrograde amnesia was assessed in demented and non-demented Parkinson’s patients using a test of remote memory spanning the years from 1920-1979. Results indicated that the demented patients 1) scored significantly below normal controls and 2) had equal impairment for all time periods. This pattern was like that seen in other dementing illnesses (i.e., Huntington’s and Alzheimer’s diseases), but different from that in amnesic disorders, such as Korsakoff s syndrome. The data, therefore, suggest qualitative differences in pattern of remote memory loss between the dementias and amnesic syndromes.

An NMR-based lipidomic approach to identify Parkinson's disease-stage specific lipoprotein–lipid signatures in plasma

The Analyst ◽  
2019 ◽  
Vol 144 (4) ◽  
pp. 1334-1344 ◽  
Author(s):  
Consuelo Pizarro ◽  
Isabel Esteban-Díez ◽  
María Espinosa ◽  
Fernando Rodríguez-Royo ◽  
José-María González-Sáiz
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Differential Diagnosis ◽  
Disease Stage ◽  
Lipoprotein Lipid ◽  
Alzheimer’S Diseases ◽  
Alzheimer's Diseases

An NMR-based lipidomic approach has been applied to provide an optimal discrimination strategy for differential diagnosis of Parkinson's and Alzheimer's diseases and for staging purposes of Parkinson's patients.

scholarly journals Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment

2021 ◽  
pp. 1-12
Author(s):  
Julie Chandler ◽  
Radhika Nair ◽  
Kevin Biglan ◽  
Erin A. Ferries ◽  
Leanne Munsie ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Emergency Department ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Memory Loss ◽  
Patient Characteristics ◽  
Emergency Department Visits ◽  
Administrative Claims ◽  
Newly Diagnosed ◽  
Comorbidity Burden

Background: Characterizing patients with Parkinson’s disease (PD) and cognitive impairment is important toward understanding their natural history. Objective: Understand clinical, treatment, and cost characteristics of patients with PD pre- and post-cognitive impairment (memory loss/mild cognitive impairment/dementia or dementia treatment) recognition. Methods: 2,711 patients with PD newly diagnosed with cognitive impairment (index) were identified using administrative claims data. They were matched (1:1) on age and gender to patients with PD and no cognitive impairment (controls). These two cohorts were compared on patient characteristics, healthcare resource utilization, and total median costs for 3 years pre- and post-index using Chi-square tests, t-tests, and Wilcoxon rank-sum tests. Logistic regression was used to identify factors predicting cognitive impairment. Results: Comorbidity indices for patients with cognitive impairment increased during the 6-year study period, especially after the index. Enrollment in Medicare Advantage Prescription Drug plans vs. commercial (OR = 1.60), dual Medicare/Medicaid eligibility (OR = 1.36), cerebrovascular disease (OR = 1.24), and PD medication use (OR = 1.46) were associated with a new cognitive impairment diagnosis (all p <  0.05). A greater proportion of patients with cognitive impairment had hospitalizations and emergency department visits and higher median total healthcare costs than controls for each year pre- and post-index. Conclusion: In patients with PD newly diagnosed with cognitive impairment, comorbidity burden, hospitalizations, emergency department visits, and total costs peaked 1-year pre- and post-identification. These data coupled with recommendations for annual screening for cognitive impairment in PD support the early diagnosis and management of cognitive impairment in order to optimize care for patients and their caregivers.

scholarly journals Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-αAgonist in Cognitive Impairment in Parkinson’s Disease: Behavioral, Biochemical, and PBPK Profile

PPAR Research ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Dedeepya Uppalapati ◽  
Nihar R. Das ◽  
Rahul P. Gangwal ◽  
Mangesh V. Damre ◽  
Abhay T. Sangamwar ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Neurodegenerative Disorder ◽  
Memory Loss ◽  
Pbpk Modeling ◽  
Pharmacokinetic Parameters ◽  
Peroxisome Proliferator ◽  
Fenofibric Acid ◽  
Peroxisome Proliferator Activated Receptor

Parkinson’s disease (PD) is a common neurodegenerative disorder affecting 1% of the population by the age of 65 years and 4-5% of the population by the age of 85 years. PD affects functional capabilities of the patient by producing motor symptoms and nonmotor symptoms. Apart from this, it is also associated with a higher risk of cognitive impairment that may lead to memory loss, confusion, and decreased attention span. In this study, we have investigated the effect of fenofibrate, a PPAR-αagonist in cognitive impairment model in PD. Bilateral intranigral administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (100 µg/1 µL/side) produced significant cognitive dysfunctions. Fenofibrate treatment at 10, 30, and 100 mg/kg for twenty-five days was found to be neuroprotective and improved cognitive impairment in MPTP-induced PD model as evident from behavioral, biochemical (MDA, GSH, TNF-α, and IL-6), immunohistochemistry (TH), and DNA fragmentation (TUNEL positive cells) studies. Further, physiologically based pharmacokinetic (PBPK) modeling study was performed using GastroPlus to characterize the kinetics of fenofibric acid in the brain. A good agreement was found between pharmacokinetic parameters obtained from the actual and simulated plasma concentration-time profiles of fenofibric acid. Results of this study suggest that PPAR-αagonist (fenofibrate) is neuroprotective in PD-induced cognitive impairment.

scholarly journals Rare VPS35 A320V Variant in Taiwanese Parkinson’s Disease Indicates Disrupted CI-MPR Sorting and Impaired Mitochondrial Morphology

2020 ◽  
Vol 10 (11) ◽  
pp. 783
Author(s):  
Yih-Ru Wu ◽  
Chih-Hsin Lin ◽  
Chih-Ying Chao ◽  
Chia-Wen Chang ◽  
Chiung-Mei Chen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Genetic Variants ◽  
Late Onset ◽  
Mitochondrial Morphology ◽  
Mitofusin 2 ◽  
Ubiquitin Protein Ligase ◽  
Vacuolar Protein ◽  
Cdna Fragments ◽  
Normal Controls

Sequence variants in vacuolar protein sorting 35 (VPS35) have been reported to be associated with Parkinson’s disease (PD). To investigate if the genetic variants in VPS35 contribute to Taiwanese PD, VPS35 cDNA fragments from 62 patients with PD were sequenced. A cohort of PD (n = 560) and ethnically matched controls (n = 506) were further examined for the identified mutation. The effects of the mutation on cation-independent mannose-6-phosphate receptor (CI-MPR) sorting and mitochondrial morphology were further examined in 293T cells expressing the mutant VPS35. Here, a novel heterozygous A320V in the VPS35 gene was identified in two late-onset PD (LOPD) patients, which was absent in 506 normal controls. Expression of the A320V mutant in 293T cells demonstrated increased colocalization of VPS35 with CI-MPR and decreased CI-MPR and lysosomal-associated membrane protein 2 (LAMP2) levels. Decreased CI-MPR manifested in missorting of cathepsin D and decreased proteolysis of α-synuclein. A320V mutation also increased mitochondrial E3 ubiquitin protein ligase 1 (MUL1) and thus led to mitofusin 2 (MFN2) degradation. The results suggest that the expression of VPS35 A320V leads to disrupted CI-MPR sorting and impaired mitochondrial morphology, which may partly explain its action in PD.

Differentiating Patients with Parkinson’s Disease from Normal Controls Using Gray Matter in the Cerebellum

2016 ◽  
Vol 16 (1) ◽  
pp. 151-157 ◽  
Author(s):  
Ling-Li Zeng ◽  
Liang Xie ◽  
Hui Shen ◽  
Zhiguo Luo ◽  
Peng Fang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Gray Matter ◽  
Normal Controls

Remote memory in Parkinson's disease and senile dementia

1997 ◽  
Vol 35 (4) ◽  
pp. 547-557 ◽  
Author(s):  
B Leplow ◽  
Ch Dierks ◽  
P Herrmann ◽  
N Pieper ◽  
R Annecke ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Senile Dementia ◽  
Remote Memory

scholarly journals Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease

2007 ◽  
Vol 28 (3) ◽  
pp. 441-444 ◽  
Author(s):  
Roger L Albin ◽  
Robert A Koeppe ◽  
Nicolaas I Bohnen ◽  
Kristine Wernette ◽  
Michael A Kilbourn ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Positron Emission Tomography ◽  
Parkinson's Disease ◽  
Serotonin Transporter ◽  
Emission Tomography ◽  
Serotoninergic Neurons ◽  
Positron Emission ◽  
Brainstem Nuclei ◽  
Early Parkinson’S Disease ◽  
Normal Controls

Postmortem data indicate loss of serotoninergic neurons in Parkinson's disease (PD). We used the serotonin transporter (SERT) radioligand 3-amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitril (DASB) and positron emission tomography to examine SERT distribution and changes in early PD subjects. We studied five PD subjects (H&Y 1 to 2.5) and eight normal controls. There is reduced SERT binding in PD. The magnitude of DASB binding reductions was greater in the forebrain than in the brainstem regions. There was no asymmetry of diminished SERT binding. DASB binding in the medulla was relatively spared, inconsistent with the description of early prominent pathologic study in these caudal brainstem nuclei.

Cognitive Profile of the Earliest Stage of Dementia in Parkinson’s Disease

2012 ◽  
Vol 27 (8) ◽  
pp. 614-619 ◽  
Author(s):  
Mariya Petrova ◽  
Margarita Raycheva ◽  
Latchezar Traykov
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Episodic Memory ◽  
Executive Functions ◽  
Mini Mental State Examination ◽  
Early Stage ◽  
Considerable Controversy ◽  
State Examination ◽  
Normal Controls ◽  
Specific Profile

Recently, a strong interest has emerged in recognizing Parkinson’s disease dementia (PDD) at a very early stage. However, the specific profile of the earliest stages of PDD is still unclear and a matter of considerable controversy. The objective of this study was to find out early neuropsychological markers for progression of dementia in this population. Fifty-eight patients with PDD were divided into 2 subgroups on the basis of the Mini-Mental State Examination: very mild and mild. The comparison with 26 normal controls shows that very mild PDD had deficits on attention/executive functions, naming, visuospatial/constructional abilities and retrieval of the episodic memory. Patients with mild PDD showed additional deficits on coding of episodic memory. Moreover, we found that in this early stage of PDD, the progression of dementia is mainly related to deterioration of attention/executive functions as well as retrieval and coding of episodic memory.

Sign in / Sign up

Export Citation Format

Share Document